403 related articles for article (PubMed ID: 15983956)
1. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
Bianchi S; Bigazzi R; Campese VM
Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
Bianchi S; Bigazzi R; Campese VM
Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949
[TBL] [Abstract][Full Text] [Related]
3. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
Clin J Am Soc Nephrol; 2009 Mar; 4(3):542-51. PubMed ID: 19261819
[TBL] [Abstract][Full Text] [Related]
6. Mineralcorticoid receptor blockers in chronic kidney disease.
Erraez S; López-Mesa M; Gómez-Fernández P
Nefrologia (Engl Ed); 2021; 41(3):258-275. PubMed ID: 36166243
[TBL] [Abstract][Full Text] [Related]
7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
8. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
[TBL] [Abstract][Full Text] [Related]
9. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
10. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
Kim HY; Bae EH; Ma SK; Kim SW
Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
[TBL] [Abstract][Full Text] [Related]
11. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
González Monte E; Andrés A; Polanco N; Toribio MJ; Santana R; Gutiérrez Martínez E; González J; Ramírez E; Hernández A; Morales E; Praga M; Morales JM
Transplant Proc; 2010 Oct; 42(8):2899-901. PubMed ID: 20970564
[TBL] [Abstract][Full Text] [Related]
12. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
Van Buren PN; Adams-Huet B; Nguyen M; Molina C; Toto RD
Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116
[TBL] [Abstract][Full Text] [Related]
13. [The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
Morales E; Huerta A; Gutiérrez E; Gutiérrez Solís E; Segura J; Praga M
Nefrologia; 2009; 29(5):421-9. PubMed ID: 19820754
[TBL] [Abstract][Full Text] [Related]
14. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
15. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
Bianchi S; Bigazzi R; Campese VM
Am J Kidney Dis; 2010 Apr; 55(4):671-81. PubMed ID: 20097461
[TBL] [Abstract][Full Text] [Related]
16. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
Edwards NC; Steeds RP; Chue CD; Stewart PM; Ferro CJ; Townend JN
Br J Clin Pharmacol; 2012 Mar; 73(3):447-54. PubMed ID: 21950312
[TBL] [Abstract][Full Text] [Related]
17. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
Bomback AS; Kshirsagar AV; Amamoo MA; Klemmer PJ
Am J Kidney Dis; 2008 Feb; 51(2):199-211. PubMed ID: 18215698
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
[TBL] [Abstract][Full Text] [Related]
20. Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease.
Sengul E; Sahin T; Sevin E; Yilmaz A
Ren Fail; 2009; 31(10):928-32. PubMed ID: 20030528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
